Dr. Paul M. Barr
Claim this profileUniversity of Rochester
Expert in Cancer
Expert in Lymphoma
75 reported clinical trials
147 drugs studied
About Paul M. Barr
Education:
- Earned an MD from Northeast Ohio Medical University in 2000.
Experience:
- Completed internship, residency, and chief residency at Case Western Reserve University.
- Fellowship in Hematology and Oncology at Case Western.
- Holds subspecialty certification in Hematology and Oncology.
- Serves as an Associate Professor of Medicine at the University of Rochester.
- Director of the Clinical Trials Office for the Wilmot Cancer Institute.
Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage III
2Lymphoma
Global LeaderStage IV
CCND1 positive
t(11;14) positive
Affiliated Hospitals
Clinical Trials Paul M. Barr is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.
Recruiting2 awards Phase 34 criteria
More about Paul M. Barr
Clinical Trial Related5 years of experience running clinical trials · Led 75 trials as a Principal Investigator · 40 Active Clinical TrialsTreatments Paul M. Barr has experience with
- Nivolumab
- Cisplatin
- Pembrolizumab
- Cyclophosphamide
- Ipilimumab
- Carboplatin
Breakdown of trials Paul M. Barr has run
Cancer
Lymphoma
Leukemia
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paul M. Barr specialize in?
Paul M. Barr focuses on Cancer and Lymphoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage I.
Is Paul M. Barr currently recruiting for clinical trials?
Yes, Paul M. Barr is currently recruiting for 39 clinical trials in Rochester New York. If you're interested in participating, you should apply.
Are there any treatments that Paul M. Barr has studied deeply?
Yes, Paul M. Barr has studied treatments such as Nivolumab, Cisplatin, Pembrolizumab.
What is the best way to schedule an appointment with Paul M. Barr?
Apply for one of the trials that Paul M. Barr is conducting.
What is the office address of Paul M. Barr?
The office of Paul M. Barr is located at: University of Rochester, Rochester, New York 14642 United States. This is the address for their practice at the University of Rochester.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.